Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway

Gastroenterology

Volumn 121, Issue 5, 2001, Pages 1145-1157

  Lügering, Andreas ^a   Schmidt, Michael ^a   Lügering, Norbert ^a   Pauels, Hans Gerd ^a   Domschke, Wolfram ^a   Kucharzik, Torsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ANTIGEN; INFLIXIMAB; LIPOCORTIN 5; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKOPENIA; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 0034754480     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.28702     Document Type: Article

References (48)

1. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in CD
2. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial
3. Infliximab for the treatment of fistulas in patients with Crohn’s disease
4. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease
5. Tumor necrosis factor: Biology and therapeutic inhibitors
6. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease
7. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
8. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease
9. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
10. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease
11. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease
12. The cell biology of macrophage activation
13. Lymphocytes play the music but the macrophage calls the tune
14. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa
15. Current concept of the role of monocytes/macrophages in inflammatory bowel disease-balance of proinflammatory and immunosuppressive mediators
16. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease
17. The pathophysiology of tumor necrosis factors
18. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells
19. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
20. Expression of granulocyte-macrophage colony-stimutating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-alpha
21. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
22. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
23. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short-term cellular and molecular effects
24. Importance of combined treatment with IL-10 and IL-4, but not 1L-13, for inhibition of monocyte release of the Ca(2+)-binding protein MRP8/14
25. Glucocorticoids induce apoptosis in human monocytes: Potential role of IL-1 beta
26. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils
27. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages
28. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease
29. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease
30. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
31. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
32. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis
33. Interleukin 4 down-regulates the expression of CD14 in normal human monocytes
34. IL-10 induces apoptosis in monocytes involving the CD95/CD95L pathway
35. Role of CD95/CD95L in glucocorticoid induced monocyte apoptosis
36. Regulation of human monocyte apoptosis by the CD14 molecule
37. The role of caspases in development, immunity, and apoptotic signal transduction: Lessons from knockout mice
38. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction
39. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death
40. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - Inducing signaling complex
41. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor
42. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
43. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
44. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-ependent activation of caspase-3
45. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
46. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis
47. Apoptosis
48. Mechanisms and genes of cellular suicide